Submitted by Anonymous (not verified) on 24 April 2026 - 9:10
Human medicines European public assessment report (EPAR): Vysribli (previously Denosumab Intas), Vysribli, Date of authorisation: 17/11/2025, Revision: 1, Status: Authorised
Source: